Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target raised by analysts at Piper Sandler from $2.00 to $2.50. They now have a "neutral" rating on the stock.

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.